MTOR and sarcoma: The experimental results demonstrated that the knockdown of KRT17 could efficiently decrease the cell viability (Figure 1A(ii)) and cell mobility of aRMS cells, which may result from AKT/mTOR pathway which was confirmed in other types of sarcomas (Figure 1B) [35].